Rani Therapeutics Holdings (RANI) Net Cash Flow (2020 - 2026)
Rani Therapeutics Holdings' Net Cash Flow history spans 7 years, with the latest figure at -$9.0 million for Q1 2026.
- On a quarterly basis, Net Cash Flow fell 241.39% to -$9.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$770000.0, a 123.81% decrease, with the full-year FY2025 number at $14.6 million, up 792.48% from a year prior.
- Net Cash Flow came in at -$9.0 million for Q1 2026, down from $14.2 million in the prior quarter.
- The five-year high for Net Cash Flow was $14.2 million in Q4 2025, with the low at -$69.5 million in Q3 2022.
- Historically, Net Cash Flow has averaged -$6.3 million across 5 years, with a median of -$2.4 million in 2024.
- Peak annual rise in Net Cash Flow hit 2850.68% in 2025, while the deepest fall reached 2477.64% in 2025.
- Year by year, Net Cash Flow stood at -$212000.0 in 2022, then soared by 520.75% to $892000.0 in 2023, then crashed by 157.74% to -$515000.0 in 2024, then skyrocketed by 2850.68% to $14.2 million in 2025, then tumbled by 163.37% to -$9.0 million in 2026.
- Business Quant data shows Net Cash Flow for RANI at -$9.0 million in Q1 2026, $14.2 million in Q4 2025, and -$6.1 million in Q3 2025.